Assessing Cosopt Switch Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00273442 |
Recruitment Status :
Completed
First Posted : January 9, 2006
Last Update Posted : November 19, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ocular Hypertension Open-Angle Glaucoma Exfoliation Syndrome Glaucoma, Pigmentary | Drug: timolol maleate Drug: dorzolamide/timolol maleate fixed combination | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | November 2005 |
Actual Study Completion Date : | April 2007 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
- the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
- visual acuity should be 20/200 or better in each eye
Exclusion Criteria:
- contraindications to study drugs
- anticipated change in systemic hypotensive therapy during the trial
- use of any corticosteroids by any route in the three months immediately prior to Visit 2

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273442
United States, Arkansas | |
Little Rock Eye Clinic | |
Little Rock, Arkansas, United States, 72205 | |
United States, Georgia | |
Omni Eye Services | |
Atlanta, Georgia, United States, 30342 | |
United States, Illinois | |
Midwest Eye Center | |
Bourbonnais, Illinois, United States, 60914 | |
United States, Oklahoma | |
Mark J. Weiss, MD | |
Tulsa, Oklahoma, United States, 74104 | |
United States, South Carolina | |
Glaucoma Consultants & Center for Eye Research | |
Mt. Pleasant, South Carolina, United States, 29464 |
Study Director: | William C. Stewart, MD | Pharmaceutical Research Network, LLC | |
Principal Investigator: | Mark J. Weiss, MD | ||
Principal Investigator: | Douglas G. Day, MD | Omni Eye Services | |
Principal Investigator: | Sriram Sonty, MD, FACS | Midwest Eye Center | |
Principal Investigator: | J. Charles Henry, MD | Little Rock Eye Clinic | |
Principal Investigator: | Elizabeth D. Sharpe, MD | Glaucoma Consultants & Center for Eye Research |
ClinicalTrials.gov Identifier: | NCT00273442 |
Other Study ID Numbers: |
PRN 05-007 |
First Posted: | January 9, 2006 Key Record Dates |
Last Update Posted: | November 19, 2008 |
Last Verified: | November 2008 |
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Exfoliation Syndrome Eye Diseases Iris Diseases Uveal Diseases Timolol Dorzolamide Maleic acid |
Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Carbonic Anhydrase Inhibitors |